..................................................
I will delete posts that are
solicitation from a pump site
or solicitation of us by salesmen
..................................................
$NEXCF at resistance $0.88
OTC/QB avg daily volume (low) 16k website hold x 100% sell filings and news 3/27/2020
$6 million in Revenues Period Ended December 31st 2019
$SHMP looking for a bottom $0.027
OTC/QB - made a ton of money the 1st run ($0.02)
Avg daily Volume 440k
Now looking for a bottom play re entry. A Game Changer stock.
Perfected clean "farming" of salt water shrimp and fish. Website float 300.64m
100% sell filings and news 3/18/20 a fire has destroyed the main building
Note:
We are adopting a policy
of barring and deleting paid humps and the like !!
I will delete any paid promo. They come here to make
some use of our casual stock sharing environment.
Good riddance.
Sign in the entrance window:
We will also delete any so-called market research
advertisement or any post fronting such off-site and
any off-site email sign-up or company solicitation.
< All foreign exchange stocks are welcome so long
as their exchange is clearly shown each posting.
A word to the wise:
"Stock picking is work".
"The stock market
is all about work."
"Just you and it "
We follow stocks with a low float < 100M
and stocks with an ultra low float < 30M.
But whatever is moving well, makes a1list.
Charts qualify that are looking up in some way:
on a moving average at resistance or support,
or with a staging formation such as a bull flag.
An upgrading Pr is great too.
The float shown is the highest number
from OTCMarkets-YahooFinance-WSJournal.
I use the highest of any two I look at.
Re: O/S Checked against SEC filings.
ZEISS Sets Sights on China’s Myopia Epidemic They're calling myopia a public health crisis in China, and if you've seen the statistics, that's no exaggeration. Enter ZEISS Medical Technology, angling for a piece of the pie with their newly NMPA-approved PT LUNANA phakic intraocular lens. This is more than just another medical product, folks. It's a strategic entry into...
A Strong Quarter Despite Some Knocks It ain't every day you see a company like Keenova Therapeutics clocking solid top-line growth, despite battling the waves of operational losses. Now, don't get me wrong; I ain't swooning over their near $96 million loss from continuing operations, but let me give credit where it's due—those sales numbers popped impressive. Pillars of...
Graphene Making Waves in Defense Fresh off the press, folks. First Graphene Limited is struttin' onto the US defense scene with a repeat order for its PureGRAPH®—a big deal in the realm of electrically conductive inks. The tally comes to around A$35,000 in an order from a longtime American customer. We're talking about inks that print circuits, sensors, and more,...
Hunting for the Perfect Gift? Look No Further The holiday hustle and bustle inevitably sparks one of the annual dilemmas: What on earth should you buy those grandkids of yours? No need to get all twisted up this season. Enter ZestYears, the savvy go-to guide for grandparents who want to nail gift-giving without breaking a sweat or the bank. These folks, based out of...
If you've ever punched numbers on car values, you've probably bumped into Kelley Blue Book. This icon in vehicle valuation is marking its 100th birthday with a bang—road-tripping across Route 66 to sprinkle some joy across the dusty roads of history. Nostalgia Meets the Open Road The legendary Route 66 is not just the backdrop but the beating heart of this centennial...
Building Bridges Between Work and Home Well, it’s about time someone threw in a lifeline to those drowning in Florida’s housing crisis. Tampa General Hospital, teaming up with The Michaels Organization, is setting the stage with 'The Linden': a solution pitched smack dab into the heart of affordability woes. This isn't your run-of-the-mill press release fluff. They've...
Hexnode XDR: A Game Changer for MacOS Threats Ever heard of Hexnode? Well, today's chat is all about them beefing up their XDR platform. They’ve sagely added support for macOS—finally given the platform some love alongside Windows. It's about time! This move is a big win for everyone whose daily grind depends on keeping threats at bay across platforms. We’re talking...
Partnership to Expand Digital Asset Liquidity Looks like Caladan and NextBlock just threw their hats in the ring to shake up South Korea’s institutional digital asset market. These two big guns have cooked up a strategic collaboration, aiming to bring more global liquidity into the mix. Dive into what this means for the digital asset scene in South Korea. Why This Move...
Blazing a New Trail in Automotive Excellence Who would've thought rubber on road could hit a jaw-dropping 503.17 km/h (312.65 mph)? Giti Tire just broke the mold, etching its name into the history books with the Guinness World Records™ title for their GitiSport e.GTR2 Pro tires. This isn't just about speed—it's about engineering marvel and pushing boundaries in...
Why Your Vision Might Be Blurry: It's Not Always Simple Dr. Spencer Franz isn’t just another face behind an optometry chart. He’s tackling a topic as blurry as it is relatable—your vision. You'd think a simple tweak of your glasses script might do the trick, but surprise, surprise, vision issues are sneakier than that. Changes in prescriptions are a dime a dozen,...
Assessing Cresco Labs: A Promising Investment Prospect With the cannabis market continuing to evolve, Cresco Labs Inc. stands out as an intriguing option for investors. Despite a backdrop of flat earnings and ongoing market challenges, analysts emphasize that Cresco (CRLBF) is holding the line as an "Overweight" stock. A recent analysis reveals Cresco's substantial...
Context Therapeutics Releases First Quarter 2025 Financial Results Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, made significant strides in Q1 2025, especially with its two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials. As of March 31, 2025, the company reported...
Capricor Under the Spotlight: FDA and SEC Concerns Ah, Capricor Therapeutics, Inc. (NASDAQ: CAPR)—a tale of high stakes and even higher expectations now hanging by a very taut thread. Investors are feeling the heat as the U.S. Food and Drug Administration (FDA) presses pause on Capricor's plans, and the courtroom drama unfolds with a securities class action looming over...
Wood Partners Begins Construction on Alta Flatirons The 251-unit apartment community is one of the last remaining parcels of the Downtown Superior Masterplan. Overview of Alta Flatirons National multifamily developer Wood Partners has officially commenced the development of Alta Flatirons, a significant project located in a suburb near Boulder. This community, which will...
Adobe Unveils Exciting New AI-Driven Marketing Tools Adobe Systems Incorporated (NASDAQ: ADBE) has just rolled out a game-changing suite of updates to its Adobe Experience Cloud services. These innovations are designed to help brands enhance the performance of their AI-generated marketing content significantly. With a focus on advanced analytics and the ability to...